Corcept Therapeutics Incorporated (CORT)

Liquidity ratios

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Current ratio 3.35 3.70 5.57 5.18 4.39 3.54 4.65 20.95 6.11 8.52 7.91 6.78 55.21 8.98 9.06 10.09 49.67 10.77 10.38 10.88
Quick ratio 2.72 3.01 4.70 4.23 3.52 2.91 3.90 24.99 9.83 7.47 13.26 6.04 69.74 8.07 8.15 9.19 79.72 9.96 9.60 15.88
Cash ratio 2.72 3.01 4.70 4.23 3.52 2.91 3.90 24.99 9.83 7.47 13.26 6.04 69.74 8.07 8.15 9.19 79.72 9.96 9.60 15.88

Corcept Therapeutics Incorporated's liquidity ratios indicate the company's ability to meet its short-term obligations.

1. Current Ratio: This ratio measures the company's ability to cover its short-term liabilities with its short-term assets. Corcept's current ratio has been consistently above 1, indicating a strong ability to cover its current liabilities. The ratio peaked at 55.21 on December 31, 2021, before declining to 3.35 on December 31, 2024. The company maintained a healthy current ratio above 5 for most periods, suggesting a strong liquidity position.

2. Quick Ratio: The quick ratio is a more stringent measure of liquidity as it excludes inventory from current assets. Corcept's quick ratio also showed strong liquidity levels, with most values comfortably above 1. The company had a peak quick ratio of 79.72 on December 31, 2020, and generally maintained values above 3 until a slight decline in the most recent periods, reaching 2.72 on December 31, 2024.

3. Cash Ratio: The cash ratio is the most conservative liquidity ratio, measuring the ability of a company to cover its current liabilities with only its cash and cash equivalents. Corcept's cash ratio reflected a robust liquidity position, consistently well above 1 throughout the periods analyzed. The ratio peaked at 79.72 on December 31, 2020, and remained above 2 until a decrease to 2.72 on December 31, 2024.

Overall, Corcept Therapeutics Incorporated has maintained strong liquidity ratios, indicating its ability to meet short-term obligations comfortably. However, a decreasing trend in some ratios towards the latter periods may suggest a need for closer monitoring of liquidity management to ensure continued financial health.

Additional liquidity measure

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cash conversion cycle days 416.32 299.73 355.17 343.91 435.27 450.66 436.75 1,095.13 1,154.38 419.62 1,223.58 352.24 1,240.63 351.83 332.72 363.24 1,383.43 305.03 299.78 959.57

The cash conversion cycle of Corcept Therapeutics Incorporated has shown fluctuations over the periods provided. The trend indicates that the company's ability to convert its resources into cash has varied significantly.

From March 2020 to December 2020, the cash conversion cycle increased substantially, reaching its peak at 1,383.43 days in December 2020. This high value suggests that the company took longer to convert its investments into cash during that period.

However, starting from March 2021, the cash conversion cycle began to decrease, indicating an improvement in the company's efficiency in managing its cash flow. The cycle continued to fluctuate between moderate to high levels in the subsequent quarters until September 2024, where it reached 299.73 days, showing an increase in efficiency in cash conversion.

Overall, the company's cash conversion cycle has displayed volatility, but the recent decrease in days indicates a positive trend in the company's ability to efficiently convert its investments into cash. Monitoring this ratio over time will be crucial to assess Corcept Therapeutics Incorporated's liquidity and operational efficiency in the future.